Cathepsin K inhibitors for osteoporosis and potential off-target effects

By Brömme Dieter   Lecaille Fabien  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 585-600

Informa Healthcare

Access to resources Recommend Favorite

Association between Vitamin K Epoxide Reductase (VKORC1) -1639G>A Polymorphism and Osteoporosis in Postmenopausal Women

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 18, Iss. 3, 2018-04 ,pp. : 281-286

Bentham Science Publishers

Access to resources Recommend Favorite

Somatotropin and somatostatin effects on vitamin K-dependent plasma coagulation factors

By Negrev N.   Nyagolov Y.   Stanchewa E.  

European Journal of Pharmacology, Vol. 277, Iss. 2, 1995-04 ,pp. : 145-149

Elsevier

Access to resources Recommend Favorite

Contribution of CYP2C9 to variability in vitamin K antagonist metabolism

By Daly Ann K   King Barry P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 2, Iss. 1, 2006-02 ,pp. : 3-15

Informa Healthcare

Access to resources Recommend Favorite

Cathepsin K as a target for the treatment of osteoporosis

By Smith W.W.   Abdel-Meguid S.S.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 683-694

Informa Healthcare

Access to resources Recommend Favorite